Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Manchester Rare Disease Showcase

Join Beacon for Rare Diseases and the rare disease community at the Manchester Rare Disease Showcase 2025!

26 Nov 2025 | Bridgewater Hall, Manchester

Through talks, panels, and discussions, explore pressing themes, such as:

· The relationship between health inequalities and rare diseases

· Innovations in research and drug development for children and young people

· The power of patient advocacy in creating societal change

· The UK Rare Disease Framework and the impact of the NHS 10-year plan

Coulter Partners appoints Sabine Moravi as Associate Partner

LONDON, UK and BASEL, Switzerland - September 25, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, announces the appointment of Sabine Moravi as an Associate Partner. This strategic hire marks a significant step in the firm’s expansion within the Swiss market and the broader DACH region.

Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

Arecor Therapeutics plc
(“Arecor” or the “Company”)

Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million

U.S. Food and Drug Administration Authorizes CytoCell KMT2A Breakapart FISH Probe Kit PDx as a New Companion Diagnostic for KMT2A rearranged Acute Leukaemia

Oxford, UK – 22nd September 2025. OGT, a leading global provider of genomic diagnostic and research solutions, announced today that the U.S. Food and Drug Administration (FDA) has granted their De Novo Classification Request for the CytoCell® KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor, REVUFORJ® (revumenib).

ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK

• Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role
• Expanded senior team across clinical, CMC, regulatory and business development in the US and UK
• Global leader in developing a novel and highly differentiated payload class for ADCs, NMTi (N-myristoyltransferase inhibitors), to address the critical need to overcome payload resistance and improve tolerability

Subscribe to